Schedule II & RFK ·
BPC-157, a synthetic peptide derived from a gastric protein, has been widely used in research and, informally, in clinical practice despite lacking FDA approval. In 2023 FDA placed BPC-157 on a list of bulk substances that posed compounding concerns, effectively limiting its availability through US compounding pharmacies. The 2026 HHS peptide policy review has specifically reconsidered BPC-157's status. Public comments submitted by researchers and clinicians have argued for expanded access for research and limited clinical use, while FDA has reiterated safety concerns related to the absence of controlled trials. The debate remains unresolved as of April 2026.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.